Thermo Fisher to Acquire Solventum’s Purification & Filtration Business for $4.1 Billion

• Thermo Fisher Scientific has agreed to acquire Solventum’s Purification & Filtration business for $4.1 billion in cash.

• The transaction is expected to close by the end of 2025, pending regulatory approvals and customary closing conditions.

Thermo Fisher Scientific Inc. has signed a definitive agreement to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash. The deal, expected to close by the end of 2025, will enhance Thermo Fisher’s bioproduction capabilities and expand its filtration technology offerings.

Solventum’s Purification & Filtration business provides purification and filtration solutions used in biologics manufacturing, medical technologies, and industrial applications. The business operates globally across multiple regions and employs approximately 2,500 people. In 2024, it generated about $1 billion in revenue.

The acquisition will complement Thermo Fisher’s existing bioproduction portfolio, particularly in cell culture media and single-use technologies. The integration of Solventum’s filtration solutions will support both upstream and downstream workflows in biologics development and manufacturing.

“The addition of Solventum’s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders,” said Marc N. Casper, chairman, president, and CEO of Thermo Fisher. “Solventum’s portfolio of solutions will be valued by our customers and further demonstrate our disciplined capital deployment strategy.”

Once the transaction is complete, Solventum’s Purification & Filtration business will become part of Thermo Fisher’s Life Sciences Solutions segment. The company expects mid- to high-single digit organic growth and approximately $125 million in adjusted operating income synergies within five years. While the deal is expected to be slightly dilutive to adjusted EPS in the first year, long-term financial benefits include margin expansion and strong synergy realization.

The completion of the acquisition is subject to regulatory approvals and customary closing conditions. Upon closing, Thermo Fisher will further integrate Solventum’s filtration technologies into its bioprocessing portfolio, strengthening its position in the growing biologics manufacturing sector.